Have a feature idea you'd love to see implemented?
Let us know!
XGN Exagen Inc
Price (delayed)
$4.1
Market cap
$72.31M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.94
Enterprise value
$73.55M
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and
Highlights
The EPS has grown by 49% YoY and by 3.1% from the previous quarter
The company's net income rose by 48% YoY and by 2.2% QoQ
The company's gross profit rose by 18% YoY but it fell by 2.2% QoQ
Exagen's equity has plunged by 53% YoY and by 27% from the previous quarter
XGN's quick ratio is down by 20% year-on-year and by 7% since the previous quarter
Key stats
What are the main financial stats of XGN
Market
Valuations
Earnings
Shares outstanding
17.64M
Market cap
$72.31M
Enterprise value
$73.55M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.54
Price to sales (P/S)
1.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.32
Revenue
$55.75M
EBIT
-$14.66M
EBITDA
-$11.96M
Free cash flow
-$5.75M
Per share
Balance sheet
Liquidity
EPS
-$0.94
Free cash flow per share
-$0.31
Book value per share
$0.74
Revenue per share
$3.05
TBVPS
$2.39
Total assets
$43.61M
Total liabilities
$30.74M
Debt
$23.27M
Equity
$12.87M
Working capital
$26.78M
Debt to equity
1.81
Current ratio
4.05
Quick ratio
3.58
Net debt/EBITDA
-0.1
Margins
Efficiency
Dividend
EBITDA margin
-21.5%
Gross margin
58.8%
Net margin
-30.4%
Operating margin
-27.6%
Return on assets
-33.7%
Return on equity
-92.6%
Return on invested capital
-40.6%
Return on capital employed
-42.1%
Return on sales
-26.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XGN stock price
How has the Exagen stock price performed over time
Intraday
4.59%
1 week
37.58%
1 month
44.88%
1 year
162.82%
YTD
106.03%
QTD
32.69%
Financial performance
How have Exagen's revenue and profit performed over time
Revenue
$55.75M
Gross profit
$32.78M
Operating income
-$15.4M
Net income
-$16.93M
Gross margin
58.8%
Net margin
-30.4%
The operating margin has soared by 56% YoY
XGN's net margin has soared by 52% year-on-year
The operating income has soared by 52% year-on-year and by 2.6% since the previous quarter
The company's net income rose by 48% YoY and by 2.2% QoQ
Growth
What is Exagen's growth rate over time
Valuation
What is Exagen stock price valuation
P/E
N/A
P/B
5.54
P/S
1.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.32
The EPS has grown by 49% YoY and by 3.1% from the previous quarter
XGN's price to book (P/B) is 152% higher than its last 4 quarters average of 2.2 and 131% higher than its 5-year quarterly average of 2.4
Exagen's equity has plunged by 53% YoY and by 27% from the previous quarter
The P/S is 91% more than the last 4 quarters average of 0.7 but 46% less than the 5-year quarterly average of 2.5
Exagen's revenue has increased by 8% YoY
Efficiency
How efficient is Exagen business performance
The ROS has soared by 55% YoY
The company's return on invested capital rose by 34% YoY but it fell by 4.6% QoQ
Exagen's return on assets has increased by 25% YoY but it has decreased by 6% QoQ
The company's return on equity fell by 17% QoQ
Dividends
What is XGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XGN.
Financial health
How did Exagen financials performed over time
The total assets is 42% greater than the total liabilities
The total assets has declined by 28% year-on-year and by 12% since the previous quarter
XGN's quick ratio is down by 20% year-on-year and by 7% since the previous quarter
XGN's debt is 81% greater than its equity
The debt to equity has soared by 106% YoY and by 35% from the previous quarter
Exagen's equity has plunged by 53% YoY and by 27% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.